Veglio F, Pinna G, Bisbocci D, Rabbia F, Piras D, Chiandussi L
Institute of Patologia Medica B, Hypertension Unit, University of Turin, S. Vito Hospital, Italy.
J Hum Hypertens. 1990 Oct;4(5):579-82.
We evaluated the efficacy and tolerance of a dihydropyridine calcium antagonist, nicardipine slow release, in eight patients with idiopathic aldosternism. Nicardipine (80 mg/day) was given orally for 12 weeks and no dietary restrictions were imposed. During the study measurements were made of supine blood pressure, plasma renin activity, plasma aldosterone concentration, and serum potassium. Nicardipine lowered systolic and diastolic blood pressure to normal, plasma aldosterone was reduced and serum potassium levels were increased. Basal renin concentration was not altered by nicardipine. There were no side effects sufficient to cause withdrawal from the study. These results suggest that nicardipine, for efficacy and tolerance, may represent an alternative among Ca2+ channel blockers, either controlling blood pressure or reducing aldosterone levels in patients with idiopathic aldosteronism.
我们评估了一种二氢吡啶类钙拮抗剂——缓释尼卡地平，对8例特发性醛固酮增多症患者的疗效和耐受性。口服尼卡地平（80毫克/天），持续12周，且未施加饮食限制。研究期间测量了仰卧位血压、血浆肾素活性、血浆醛固酮浓度和血清钾。尼卡地平使收缩压和舒张压降至正常，血浆醛固酮降低，血清钾水平升高。尼卡地平未改变基础肾素浓度。没有足以导致退出研究的副作用。这些结果表明，就疗效和耐受性而言，尼卡地平可能是钙通道阻滞剂中的一种选择，可用于控制特发性醛固酮增多症患者的血压或降低醛固酮水平。
